<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aneurysmal <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) affects approximately 27,000 Americans per year </plain></SENT>
<SENT sid="1" pm="."><plain>Although delayed <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> is of high clinical significance, mortality within the first 2 days may approach 30% </plain></SENT>
<SENT sid="2" pm="."><plain>In this issue of the Journal of Cerebral Blood Flow and Metabolism, Lee et al have studied the role of iron in early brain injury after experimental SAH </plain></SENT>
<SENT sid="3" pm="."><plain>They found that iron chelation with <z:chebi fb="0" ids="4356">deferoxamine</z:chebi> reduced mortality and oxidative DNA damage, and lessened the induction of iron-handling proteins </plain></SENT>
<SENT sid="4" pm="."><plain>Taken together, these results highlight the deleterious potential of blood breakdown products and provide an insight into future intervention </plain></SENT>
</text></document>